Novel Therapeutic Protein Delivery Systems for Respiratory, Skin, and Eye Diseases

This inventive concept leverages the core technology of the original patent to develop novel therapeutic protein delivery systems for treating respiratory diseases, skin conditions, and eye diseases, offering a more targeted and sustained approach to protein therapy.

The original patent's technology, while effective for wound healing, has limitations in terms of protein half-life and dosing requirements. This new concept addresses these limitations by applying the core technology to different industries, specifically respiratory, skin, and eye diseases, where sustained protein delivery is crucial for effective treatment.

The new claims describe systems, methods, and devices for delivering therapeutic proteins to lung tissue, skin, and eye tissue using polymer compositions comprising polycationic and polyanionic polymers. The polyanionic polymer is heparin or heparan sulfate, and the therapeutic proteins are selected from vascular endothelial growth factor (VEGF), keratinocyte growth factor (KGF), fibroblast growth factor 2 (FGF-2), and stromal cell-derived factor 1 alpha (SDF-1α). These compositions enable sustained protein delivery over a period of at least 24 hours, reducing the need for frequent dosing and improving treatment outcomes.

The new claims introduce novel applications and use cases for the original patent's technology, expanding its scope to address unmet needs in respiratory, skin, and eye diseases. The inventive step lies in the adaptation of the core technology to these new fields, resulting in a more targeted and effective approach to protein therapy.

Alternative embodiments could include varying the polymer composition, therapeutic protein selection, or delivery device design to accommodate different disease indications or patient needs. For example, a variant could incorporate additional therapeutic agents or adjust the polymer's polydispersity index to optimize protein release kinetics.

This inventive concept has significant commercial potential in the respiratory, skin, and eye disease markets, where there is a growing demand for more effective and targeted protein therapies. The market for respiratory disease treatments alone is projected to reach $XX billion by 20XX, and the skin and eye disease markets are also expected to experience significant growth.